Mavrilimumab (GM-CSFi) phase II trial of COVID-19 PNA and systemic hyperinflammation ⭐️65% risk reduction in ventilation/death ⭐️no sig difference in ventilation requirement ⭐️no serious AE Abs#LB0001 #EULAR2021 @RheumNow